Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New immunosuppressive agents for treating psoriasis].

S Ortiz-Urda1, K Rappersberger

  • 1Department of Dermatology, Stanford Medical School, Stanford, CA, USA.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|March 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated classification of hidradenitis suppurativa disease severity by convolutional neural network analyses using calibrated clinical images.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Anti-BP180 autoantibody levels at diagnosis correlate with 1-year mortality rates in patients with bullous pemphigoid.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients - a retrospective, single institution observation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

Apremilast in psoriasis - a prospective real-world study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

[Bullous Sweet's syndrome with pulmonary involvement].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2017

Psoriasis is an immune disorder driven by T-cells and cytokines, causing keratinocyte overgrowth. Immunosuppressants like Methotrexate and Ciclosporin A disrupt this cycle, offering therapeutic options.

Area of Science:

  • Immunodermatology
  • Pathophysiology of Psoriasis

Context:

  • Psoriasis is characterized by a genetically determined, immune-mediated inflammatory process.
  • An ongoing autoreactive T-helper 1 (Th-1) cell response drives the disease.
  • Cytokines like IL-2 and interferon-gamma promote keratinocyte proliferation and incomplete differentiation.

Purpose:

  • To elucidate the pathobiological mechanisms of psoriasis.
  • To review the mode of action, efficacy, and side effects of key immunosuppressive agents.
  • To discuss therapeutic strategies for psoriasis management.

Summary:

  • Psoriasis involves a complex interplay between leukocytes and keratinocytes, fueled by Th-1 responses and cytokines.
  • Keratinocytes contribute to inflammation by expressing receptors and producing cytokines.

Related Experiment Videos

  • Immunosuppressive agents, primarily targeting T-cells, can disrupt this mutual stimulation process.

    • Impact:

    • Provides a comprehensive overview of psoriasis pathogenesis.
    • Evaluates established and emerging immunosuppressive therapies for psoriasis.
    • Informs clinical decision-making for managing this chronic inflammatory skin condition.